Creation of a lipoprotein(a) model to forecast progression-free survival and severe adverse events in metastatic lung adenocarcinoma patients lacking driver genes and with PD-L1 TPS under 50% - Summary - MDSpire
Advertisement
Creation of a lipoprotein(a) model to forecast progression-free survival and severe adverse events in metastatic lung adenocarcinoma patients lacking driver genes and with PD-L1 TPS under 50%
To evaluate the prognostic value of lipoprotein(a) (LPA) in lung adenocarcinoma (LUAD) patients receiving first-line chemoimmunotherapy and to develop a model predicting progression-free survival (PFS) and grade 3/4 adverse events (G3/4 AEs).
Key Findings:
227 patients completed follow-up; AUC for 365-day PFS was 0.78 in training and 0.95 in validation cohorts.
AdaBoost was the most accurate method for predicting G3/4 AEs.
Interpretation:
High serum LPA expression is a risk factor for disease progression in metastatic driver gene-negative LUAD patients undergoing first-line chemoimmunotherapy, indicating potential for improved patient stratification.
Limitations:
The study focused only on patients with PD-L1 TPS <50% and driver gene-negative status, limiting generalizability.
Follow-up duration was relatively short at a median of 11.36 months.
Conclusion:
The developed models effectively predict PFS and G3/4 AEs, aiding in identifying patients less likely to benefit from initial chemoimmunotherapy.
